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ABSTRACT 
 Cytochrome P450 46A1 (CYP46A1 or cholesterol 24-hydroxylase) controls cholesterol elimination 
from the brain and plays a role in higher order brain functions. Genetically enhanced CYP46A1 
expression in mouse models of Alzheimer’s disease mitigates the manifestations of this disease. We 
enhanced CYP46A1 activity pharmacologically by treating 5XFAD mice, a model of rapid 
amyloidogenesis, with a low dose of the anti-HIV medication efavirenz. Efavirenz was administered from 
1 to 9 months of age, and mice were evaluated at specific time points. At one month of age, cholesterol 
homeostasis was already disturbed in the brain of 5XFAD mice. Nevertheless, efavirenz activated 
CYP46A1 and mouse cerebral cholesterol turnover during the first four months of administration. This 
treatment time also reduced amyloid burden and microglia activation in the cortex and subiculum of 
5XFAD mice as well as protein levels of amyloid precursor protein and the expression of several genes 
involved in inflammatory response. However, mouse short-term memory and long-term spatial memory 
were impaired, whereas learning in the context-dependent fear test was improved. Additional four months 
of drug administration (a total of eight months of treatment) improved long-term spatial memory in the 
treated as compared to the untreated mice, further decreased amyloid-β content in 5XFAD brain, and also 
decreased the mortality rate among male mice. We propose a mechanistic model unifying the observed 
efavirenz effects. We suggest that CYP46A1 activation by efavirenz could be a new anti-Alzheimer’s 
disease treatment and a tool to study and identify normal and pathological brain processes affected by 
cholesterol maintenance.  
Key words: CYP46A1, efavirenz, Alzheimer’s disease, 24-hydroxycholesterol, amyloid, cholesterol 
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Highlights 
 
• CYP46A1 activity was enhanced pharmacologically by the anti-HIV drug efavirenz.  
 
• CYP46A1 activation promoted cholesterol turnover in the brain of 5XFAD mice.  
 
• CYP46A1 activation reduced amyloid-β burden in the brain of 5XFAD mice. 
 
• CYP46A1 activation reduced microglial immunoreactivity in the brain of 5XFAD mice.  
 
• Efavirenz effects on behavior of 5XFAD mice were task- and treatment time-specific.  
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1. Introduction 
 
 CYP46A1 is the CNS-specific enzyme catalyzing cholesterol 24-hydroxylation, the major mechanism 
for cholesterol removal from the brain (Lund et al., 1999; Lutjohann et al., 1996). Normally, CYP46A1 
resides in the endoplasmic reticulum and is expressed in neurons of the hippocampus, cortex, and 
cerebellum (Ramirez et al., 2008). In Alzheimer’s disease, however, CYP46A1 shows prominent 
expression in astrocytes and around amyloid plaques (Bogdanovic et al., 2001; Brown et al., 2004). 
Plasma 24-hydroxycholesterol (24HC)1, a marker of CYP46A1 activity in the brain (Lutjohann and von 
Bergmann, 2003), is increased at early disease stages (Lutjohann et al., 2000) and decreased with more 
advanced disease (Bretillon et al., 2000). Intronic polymorphisms are frequent in CYP46A1 and present in 
~29-40% of the population (http://www.ncbi.nlm.nih.gov/snp). Yet, only about half of linkage studies 
establish the CYP46A1 association with Alzheimer’s disease (Russell et al., 2009).  
 Genetic manipulations in mice provide evidence for a role of CYP46A1 beyond cholesterol 
homeostasis in the brain. Indeed, severe deficiencies in spatial, associative, and motor learning, and in 
hippocampal long-term potentiation were found in Cyp46a1-/- mice (Kotti et al., 2006). These deficiencies 
were related to the reduction in isoprenoid production during cholesterol biosynthesis, which was 
downregulated in response to CYP46A1 ablation (Kotti et al., 2008; Kotti et al., 2006). Conversely, the 
spatial memory retention was enhanced in aged female mice overexpressing CYP46A1, which also had an 
increased expression of receptors for N-Methyl-D-Aspartate (Maioli et al., 2013). The activation of these 
receptors is a key mediator of long-term potentiation (Sun et al., 2016b), and 24HC was discovered to 
serve as a positive allosteric modulator of N-Methyl-D-Aspartate receptors (Paul et al., 2013; Sun et al., 
2016a). This discovery may explain, in part, improvements in cognitive function in several mouse models 
of Alzheimer’s disease, in which CYP46A1 expression was increased either by a lack of a cholesterol 
esterifying enzyme ACAT1 (Bryleva et al., 2010) or by cerebral injections of the CYP46A1-containing 
adenovirus (Burlot et al., 2015; Hudry et al., 2010). In these models, CYP46A1 overexpression also 
ameliorated amyloid burden (Bryleva et al., 2010; Hudry et al., 2010) and was suggested to: 1) change 
cholesterol content in the endoplasmic reticulum and increase degradation of amyloid precursor protein 
(APP) in the endoplasmic membranes (Bryleva et al., 2010); 2) decrease cholesterol content in the lipid 
rafts of the plasma membranes and impair amyloidogenic APP processing (Hudry et al., 2010); and 3) 
inhibit by 24HC intracellular APP trafficking (Urano et al., 2013). Unlike overexpression, Cyp46a1 
downregulation (e.g., with a short hairpin Cyp46a1 RNA) was found to be deleterious in normal mice, 
which exhibited cognitive deficits, elevated production of amyloid-β peptides and abnormal 
phosphorylation of tau (Djelti et al., 2015). Other studies reported neuronal sclerosis and epileptic activity 
in the hippocampus (Chali et al., 2015) and the phenotype of Huntington’s disease with spontaneous 
striatal neuron degeneration and motor deficits (Boussicault et al., 2016). 
 Until recently, genetic manipulations were the only means whereby CYP46A1 activity was increased 
in vivo. We were successful with a different approach based on our studies of the biochemical and 
biophysical properties of CYP46A1 (Mast et al., 2004; Mast et al., 2010; Mast et al., 2009; Mast et al., 
2012; Mast et al., 2003; Mast et al., 2013a, b; Shafaati et al., 2010; White et al., 2008). We discovered 
that CYP46A1 is an allosteric enzyme and that the administration of the anti-HIV medication efavirenz 
(EFV) to normal (C57BL/6J) mice activates CYP46A1 and cerebral cholesterol turnover in mouse brain 
(Anderson et al., 2016; Mast et al., 2014). Remarkably, the activating EFV dose in mice was only 0.09 
mg/kg body weight (Mast et al., 2014), which is much lower than that (600 mg) given daily to HIV 
patients. Herein we administered EFV to 5XFAD mice, a model of rapid amyloidogenesis (Oakley et al., 
                                                        
1 The abbreviations used are: APP, amyloid precursor protein; EFV, efavirenz; 24HC, 24-
hydroxycholesterol; Iba1, ionized calcium-binding adapter molecule 1; CS, conditioned stimulus; LXR, 
liver X receptors; MWM, Morris water maze; PBS, phosphate buffer saline; RNA-Seq, whole 
transcriptome sequencing; ThioS, Thioflavin S; US, unconditioned stimulus. 
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2006), and evaluated drug effects on cholesterol homeostasis in the brain, amyloid pathology, cognition 
and brain genome. We demonstrate that pharmacologic CYP46A1 activation reproduces the beneficial 
effects of CYP46A1 overexpression accomplished by gene manipulations and thus could immediately be 
evaluated in a clinical trial. We also identified Serpina1e and Serpina3k encoding pro-inflammatory and 
pro-amyloidogenic proteins (Sardi et al., 2011) that have never been considered in the context of 
CYP46A1 activity, increased 24HC levels and the signaling via liver X receptors (LXR), transcription 
factors controlling the expression of cholesterol-related and other genes (Chawla et al., 2001). Increased 
cholesterol turnover and 24HC levels in the brain could be the key mediators of EFV effects.  
 
2. Methods 
 
2.1. Animals  
 
 5XFAD mice were obtained by crossing 5XFAD hemizygous males on B6SJL background with wild 
type B6SJL females (The Jackson Laboratory). Only F1 males or females homozygous for the transgenes 
were used. Age-and gender-matched animals on B6SJL background served as controls. The retinal 
degeneration allele Pde6brd1 that leads to blindness was bred out of our colony. Mice were housed in the 
Animal Resource Center at Case Western Reserve University and maintained in a standard 12 h light/12 h 
dark cycle environment. Water and food were provided ab libitum. All animal procedures were approved 
by the Case Western Reserve University Institutional Animal Care and Use Committee and conformed to 
recommendations of the American Veterinary Association Panel on Euthanasia.  
 
2.2. Chemicals  
 
  The S-isomer of efavirenz (EFV, brand name Sustiva) was purchased from Toronto Research 
Chemicals Inc. 
 
2.3. EFV treatment  
 
 This was as described (Mast et al., 2014). Briefly, EFV was dissolved in drinking water at 0.42 mg/ml 
and provided to mice in light-protected bottles. On average, mice consumed every day 6.0-6.5 ml of EFV-
containing water, which was similar to the consumption of regular water and represented a 0.1 mg/day/kg 
of body weight EFV dose for a 25-g mouse drinking daily 6.25 ml of water. EFV administration was 
initiated at 1 month of age, before the development of amyloid plaques (Oakley et al., 2006), and 
continued until animals were sacrificed for evaluations. 
 
 2.4. Brain processing 
 
 Mice were fasted overnight and next morning sacrificed. The brains were isolated as described (Mast 
et al., 2011) and either processed immediately or flash-frozen in liquid nitrogen and stored at -80oC until 
further analyses. Left brain hemispheres were always used for sterol quantifications by isotope dilution 
gas chromatography-mass spectrometry following sample saponification (Mast et al., 2011). Right brain 
hemisphere were used for APP quantification by Western blot or amyloid-β peptide quantification by 
ELISA. The whole brains were used for histo- and immunohistochemistry stains after anesthetized mice 
were sequentially perfused through the heart with 30 ml of each, phosphate buffer saline (PBS) and 4% 
paraformaldehyde in PBS. The brains were then isolated, fixed for 4 days at room temperature in 4% 
paraformaldehyde in PBS, and transferred to 1% paraformaldehyde in PBS for storage at 4o C.  
 
2.5. Histo- and immunohistochemistry  
 
  The brain cryopreservation was as described (Corona et al., 2016), except the whole brain was used, 
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and sagittal sections (10 µm-thick, cut at 1.2-1.5 mm from the midline) were mounted on slides prior to 
staining. Plaque abundance was analyzed as described (Corona et al., 2016), separately with 1% aqueous 
ThioS and primary mouse 6E10 antibody (1:1,000; Covance). For the latter, the antigen retrieval was in 
88% aqueous formic acid solution for 3 min at room temperature. The 6E10 antibody was visualized with 
secondary goat anti-mouse Alexa Fluor 546 antibody (1:1,000; Life Technologies). The microglial cells 
were detected with primary rabbit antibody against ionized calcium-binding adapter molecule 1 (Iba1, 
1:1,000; Wako) and secondary goat anti-rabbit Alexa Fluor 647 antibody (1:200, Jackson 
ImmunoResearch Inc.). All images were taken on an inverted microscope (DMI 6000 B, Leica 
Microsystems) that had a Retiga EXi-Fast camera (QImaging). The images were analyzed for the total 
number and combined area of the ThioS- and 6E10-positive plaques as well as Iba1-positive cells per 
whole brain cortex or hippocampus by the Metamorph Imaging Software (Molecular Devices). Only 
signals with the 2,000-16,383 intensity, a shape factor of ≥0.2, and size of plaques from 50 to 200 µm2 for 
ThioS-stains and ≥80 µm2 for 6E10-stains and were considered for the quantifications. Similarly, signals 
with the 1,500-16,383 intensity, a shape factor of ≥0.2, and a size of ≥100 µm2 were considered for Iba1 
quantifications. 
 
2.6. Amyloid-β peptide quantifications  
 
 The right brain hemisphere was dissected from the cerebellum and brainstem followed by 
homogenate preparation as described (Schmidt et al., 2005). Soluble and insoluble amyloid-β peptides 
were extracted with 0.2% diethylamine and 70% formic acid, respectively, as described (Casali and 
Landreth, 2016), except 200 µl of the brain homogenate was used for extraction of insoluble amyloid-β 
peptides. The content of soluble and insoluble amyloid-β peptides was measured by a sandwich ELISA 
kit (KHB3482, Invitrogen) according to the manufacturer’s instructions.  
 
2.7. Western blot analysis  
 
 Homogenates (10%, w/vol) from right brain hemispheres were prepared in 20 mM Tris-HCl, pH 7.4, 
containing 250 mM sucrose, 0.5 mM EDTA, 0.5 mM EGTA, and a cocktail of protease inhibitors 
(Complete, Roche). Tissue homogenization was followed by centrifugation at 1,500 g for 15 min and the 
SDS-PAGE separation of the supernatant obtained (4 or 8 µg protein/lane) on an 4-20% Tris/Glycine 
gradient gel (Bio-Rad) for APP quantification or 50 µg protein/lane on an 16% Tris/Tricine gel (Bio-Rad) 
for the C83 and C99 fragments quantification. A nitrocellulose membrane (Li-Cor) was used for protein 
transfer, and this membrane was blocked with Li-Cor blocking buffer (Li-Cor) containing 0.1% Tween-
20. APP was visualized with primary mouse monoclonal antibody against the APP N-terminus (Anti-APP 
A4 clone 22C11, 1:10,000; EMD Millipore) (Saito et al., 2014) and secondary goat anti-mouse antibody 
IRDye 800CW (1:20,000; Li-Cor). Beta actin was used as a loading control and was detected with 
primary rabbit polyclonal antibody (1:500; Abcam) and secondary goat anti-rabbit antibody IRDye 
680RD (1:20,000, Li-Cor). C83 and C99 were visualized with primary rabbit polyclonal antibody against 
the APP C-terminus (A8717, 1:4,000; Sigma-Aldrich) (Saito et al., 2014) and secondary goat anti-rabbit 
antibody IRDye 680RD (1:20,000, Li-Cor). GAPDH was used as a loading control and was detected with 
primary mouse polyclonal antibody (1:5,000; Abcam) and secondary goat anti-mouse antibody IRDye 
800CW (1:20,000; Li-Cor).  Membranes were imaged by the Odyssey infrared imaging system (Li-Cor).  
 
2.8. Behavioral tests 
 
 Untreated and treated 5XFAD mice for evaluations at 5 month of age (each cohort of 4 females and 
12 males) were tested individually for the following tasks: Y-maze at day1; Morris water maze (MWM) 
at days 2-6; and fear conditioning memory tests at days 12 and 13 after the break at days 7-11. The Y-
maze test was performed for a short-term, working memory task as described (Arakawa et al., 2014; 
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Bryan et al., 2010) utilizing a Y-shaped maze with an arm length of 35 cm, width of 6 cm, and height of 
10 cm. Each mouse was tested for 5-14 min until the animal made 20 arms choices.  The choices of 
entered arms were then calculated to determine the alternation rate, i.e., degree of arm entries without 
repetitions. The MWM test evaluated a long-term spatial memory (Yu et al., 2014). Mice had to find an 
invisible platform when swimming in a pool. Three trials per day were performed for five consecutive 
days. Swim time and path length were recorded using an automated tracking software (ANY-maze, 
Stoelting Co.). Latencies to reach the platform during each trial were wrapped up into one day-block of 
three trials, which represented a long-term spatial learning. In addition, the fear-related memory tests 
including both context- and cue-dependent versions were performed (Ulatowski et al., 2014). Briefly, 
mice were placed in a conditioning box (Med Associates) and trained to associate the conditioned 
stimulus (CS, a pure tone of 3kHz, 80 dB for 30 sec) with co-terminated unconditioned stimulus (US, 
electrical shock of 0.5 mA for 1 sec). This fear conditioning procedure was repeated four times with 120-
sec accumulation and 60-sec inter-stimulus-interval. Twenty-four hours later, mice were placed back in 
the box with a same context and their freezing behavior in the absence of CS was measured for 5 min 
(context-dependent fear). Two hours after the context fear test, mice were reintroduced into the 
contextually altered box (shape, lighting, and odor) so that they could no longer recognize the chamber, in 
which they had been trained. Freezing behavior was measured during the first 3 min without the tone 
(non-CS) and then during the second 3 min with the tone (CS).  
 Untreated and treated 5XFAD mice for evaluations at 9 month of age comprised of 13 females and 1 
male in the untreated group and 13 females and 5 males in EFV-treated group. The behavioral tests were 
the same as at 5 months of age.  
 
2.9. Whole brain transcriptome sequencing (RNA-Seq) 
 
 One hemisphere from each of three 5XFAD mice per group (EFV-treated and untreated) was 
homogenized in 10 vol (w/v) of TRIzol reagent (Life Technologies) followed by the isolation of total 
RNA according to the manufacturer’s protocol. Individual libraries were then prepared from each RNA 
sample (500 ng in 10 µl) using the TruSeq Stranded Total RNA with RiboZero Gold kit (Illumina). Each 
library was individually tagged with a unique adapter-index and pooled together. Pooled libraries were 
run on a HiSeq 2500 System (Illumina) with 2 x 100 bp paired-end reads, and the quality of sequencing 
reads was assessed by the FastQC softwrae (Babraham Bioinformatics). Reads that passed the quality 
filters were aligned to the mouse mm10 reference genome using the TopHat software (Trapnell et al., 
2009), which implements the Bowtie 2 algorithm (Langmead and Salzberg, 2012) for sequence alignment 
and analyzes the mapped reads to identify splice junctions between exons.  The TopHat results were 
analyzed using the Cufflinks RNASeq analysis package (Trapnell et al., 2010), and the fragments per 
kilobase of exon per million fragments mapped values were reported for each gene and 
sample.  Differentially expressed genes between the control and treatment group were identified using a 
q-value (adjusted p-value for multiple testing) of ≤0.05.   
 
2.10. qRT-PCR  
 
  Total RNA (1 µg) was converted to cDNA by SuperScript III Reverse Transcriptase (Invitrogen) and 
used for qRT-PCR conducted on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). 
The sequences of the primers for gene quantifications was taken from qPrimerDepot, a primer database 
for qRT-PCR (Cui et al., 2007). PCR reactions were performed in triplicate and normalized to β-actin. 
 
2.11. Statistical analysis  
 
 All graphs represent mean ± SD, except behavioral tests, where the error bars are SEM. Data analysis 
is indicated in each figure legend and represents either unpaired Student’s t-test assuming a two-tailed 
distribution or a two-way ANOVA. Statistical significance was considered when P values were ≤ 0.05. 
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All histo- and immunohistochemistry images and Western blots are representative of observations in 3-8 
mice/per group.  
 
3. Results  
 
3.1. Cholesterol homeostasis in the 5XFAD brain is disturbed by the transgene expression but is 
responsive to EFV treatment  
 
 Three groups of animals (the background B6SJL strain, untreated and EFV-treated 5XFAD mice) 
were assessed after weaning (from 1 month of age) for monthly brain levels of cholesterol, two 
cholesterol precursors (lathosterol and desmosterol) and one cholesterol metabolite (24HC). Lathosterol 
and desmosterol are the markers of cholesterol biosynthesis in neurons and astrocytes, respectively 
(Pfrieger and Ungerer, 2011), whereas 24HC reflects cholesterol elimination from the brain, realized 
mainly via 24-hydroxylation mediated by CYP46A1 (Lund et al., 1999; Lutjohann et al., 1996). In B6SJL 
mice, a pool of cerebral cholesterol expanded until 3 months of age (Fig. 1A), whereas the cholesterol 
biosynthesis rates (the lathosterol and desmosterol levels) declined after birth (Fig. 1B,C) and the 24HC 
levels were not changing with age (Fig. 1D). Yet, after 3 months of age, i.e., in the adult brain, the levels 
of all measured sterols became steady state, consistent with previous findings in other strains of normal 
mice (Dietschy and Turley, 2004; Lund et al., 1999; Quan et al., 2003). The data obtained reveal the 
mechanism whereby cholesterol biosynthesis is balanced by cholesterol metabolism in the adult mouse 
brain; it is through a reduction in the rate of prenatal cholesterol biosynthesis (Fig. 1B,C) rather than an 
increase in the rate of postnatal 24HC production (Fig. 1D).  
 Cholesterol content and sterol dynamics were different in the brain of untreated 5XFAD mice (Fig. 
1E-H). After weaning, cerebral cholesterol was lower in these animals than in B6SJL mice, and reached 
the levels of the B6SJL brain only by 8 months of age (Fig. 1E,M). Brain lathosterol, initially the same in 
the weaned 5XFAD and B6SJL animals, decreased with age in both strains (Fig. 1F,N). Yet in 5XFAD 
mice this decrease was not as steep as in the B6SJL strain reaching the B6SJL levels only at 6-8 months. 
Then, at 9 months of age, the 5XFAD brain lathosterol began to increase again. The desmosterol levels 
were always higher in the 5XFAD brain than in the B6SJL brain and never reached those in the B6SJL 
strain (Fig. 1G,O). Finally, the 24HC levels were increased at 2-4 months in the untreated 5XFAD brain 
and then became similar to those in the B6SJL brain (Fig. 1H,P). Thus, not only was brain cholesterol 
lower in adult 5XFAD mice, but all measured sterols fluctuated with age, and the changes in cholesterol 
precursors and 24HC were not parallel. Such sterol pattern suggests that the overexpression of mutant 
human APP and/or presenilin 1 disturbed cholesterol homeostasis in the 5XFAD brain, and periodically 
uncoupled cholesterol biosynthesis from cholesterol elimination.  
 Despite the dysregulation, cholesterol homeostasis in the brain of 5XFAD mice responded to the EFV 
treatment. As compared to untreated 5XFAD mice, the drug led to a statistically significant increase in the 
brain 24HC levels beginning from 5 months of age, reflective of the activation of CYP46A1 (Fig. 1L,P) 
and consistent with our previous studies in C57BL/6J mice (Mast et al., 2014). However, in young, 2-4 
month old animals this increase was apparently not compensated by the cholesterol biosynthetic 
processes, and cholesterol was depleted from the brain of EFV-treated mice (Fig. 1I,M). Then, at 4-6 
months of age, cerebral cholesterol biosynthesis in EFV-treated mice probably became coupled to 
cerebral cholesterol metabolism, and cholesterol content in the brain began to increase. At 6 months, 
cerebral cholesterol in EFV-treated 5XFAD mice finally reached the sterol levels in the brain of the 
B6SJL mice and was subsequently stable. In contrast, in the untreated 5XFAD brain, cholesterol levels 
reached those of the B6SJL strain 2 months later. Thus, pharmacologic activation of CYP46A1 is possible 
in the brain with disturbed cholesterol maintenance and leads to a faster normalization of brain 
cholesterol.  
 On the basis of the data obtained, we selected two time points (5 and 9 months of age) for more 
expanded assessments in 5XFAD mice. At both time points, cerebral cholesterol was similar in EFV-
untreated and treated 5XFAD mice. Yet at 5 months of age, both groups had their cerebral cholesterol 
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lower than in B6SJL mice and cholesterol levels were still unstable. In contrast, at 9 months age, cerebral 
cholesterol was similar in all three groups of mice and already stabilized in 5XFAD animals. Another 
important difference between the two evaluation time points was that the 5 month-evaluations were 
preceded by a cholesterol depletion from the brain EFV-treated mice, whereas the 9 month-evaluations 
were preceded by increases in cerebral 24HC and cholesterol turnover (Fig. 1M-P).  
 
3.2. EFV treatment reduced amyloid-β pathology and microglial immunoreactivity in 5XFAD mice 
 
 The brain amyloid burden was assessed by Thioflavin S (ThioS) staining, immunohistochemistry 
using the antibody 6E10, and ELISA quantifications (Figs. 2,3). ThioS binds to β sheet-rich structures 
and visualizes amyloid dense-core plaques observed at later stages of Alzheimer’s disease (Dickson, 
1997). 6E10 interacts with amyloid-β peptides, APP and its fragment soluble APPα and detects amyloid 
diffuse-core plaques prevalent in the preclinical stages of the disease (Rozemuller et al., 1989). Four 
months of EFV treatment reduced amyloid abundance in the brain cortex and hippocampus of 5-month 
old 5XFAD mice (Figs. 2,3), the two regions that are among those affected most severely in Alzheimer’s 
disease and the first to show amyloid deposition in 5XFAD mice (Oakley et al., 2006). In the cortex, the 
total number and area of the ThioS-positive plaques was reduced by 35% and 45%, respectively (Fig. 
2B). In the hippocampus, these reductions were by 33% and 38%, respectively. The 6E10-positive 
plaques showed statistically significant reductions in the total number and area in the cortex (by 50% and 
70%, respectively), and in total area in the hippocampus (by 72%, Fig. 3B). The total number of the 
6E10-positive plaques was not significantly reduced in the hippocampus. Thus, both diffuse- and dense-
core amyloid plaques were reduced by EFV treatment in the cortex, whereas changes in the hippocampus 
were plaque morphology-dependent.    
  Immunolabeling for 6E10 was conducted simultaneously with that for Iba1, upregulated in activated 
microglial cells that surround amyloid plaques (Dickson, 1997). EFV-treatment reduced the number of 
Iba1-positive cells by 45% in the cortex and 64% in the hippocampus; similarly, a total immunoreactivity 
for Iba1 was reduced by 49% and 78% in the cortex and hippocampus, respectively (Fig. 3B).  
 The measurements by ELISA were used to discriminate between the amyloid-β1-40 and amyloid-β1-42 
species as well as between soluble and insoluble amyloid-β peptides. Insoluble amyloid-β1-42 peptide is 
predominant in the 5XFAD mice and the initial amyloid species that deposit into amyloid plaques in all 
forms of Alzheimer’s disease (Haass and Selkoe, 2007). Four and eight months of EFV treatment led to 
the same, ~30%, statistically significant reduction in the levels of insoluble amyloid-β1-42 peptide. In 
addition, a 40% reduction in the levels of insoluble amyloid-β1-40 peptide was observed after eight months 
of treatment (Fig. 3C,D). Neither treatment time affected significantly the soluble amyloid-β species. 
ELISA quantifications supported histo- and immunohistochemistry data. 
 
3.3. EFV treatment reduced the mortality rates in 5XFAD male mice  
 
 The mortality rates were determined based on animal survival in the cohorts of animals assigned for 
behavioral tests.  The cohort of 5XFAD mice for evaluations at 5 month of age (after 4 months of EFV 
administration to the treated group) comprised initially of 4 females and 16 males in the untreated group 
and 4 females and 14 males in EFV-treated group. By 5 months of age, there was no mortality among any 
of the female mice and in contrast 25% (four animals) and 14% (2 animals) of mortality among male mice 
in the untreated and EFV-treated groups, respectively. 
 The cohort of 5XFAD mice for evaluations at 9 month of age comprised initially from 13 females and 
8 males in the untreated group and 15 females and 5 males in EFV-treated group. By 9 months of age 
(after 8 months of EFV administration to the treated group), there was no mortality among female mice in 
the untreated group and 13% of mortality (two animals) in EFV-treated group. The male mortality was 
87% in the untreated group (7 animals) and zero in EFV-treated group.  
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3.4. EFV effects on behavior of 5XFAD mice were task- and treatment time-specific  
 
 EFV effects were assessed on only those memory tasks that are known to be impaired in the 5XFAD 
strain: Y-maze, MWM, and conditioned fear tests (Oakley et al., 2006; Ohno et al., 2006).  In the Y-maze 
test, which refers to hippocampus-dependent short-term spatial memory, EFV treatment had little impact 
on memory performance. The alteration rate was slightly reduced after 4 months of drug treatment and 
was similar in the untreated and treated groups after 8 months of EFV administration (Fig. 4A). In the 
MWM test, a long-term spatial memory test, no learning through the trials was observed in the treated 
group after 4 months of EFV administration whereas the untreated group of the same age (5-month old) 
displayed steadily increasing learning performance (Fig. 4B). However, the treated group showed better 
learning performance than the untreated controls when tested after 8 months of EFV treatment at 9 
months old. Moreover, the treated 9-month old mice even demonstrated some resistance to age-related 
behavioral deterioration that is known to occur in 5XFAD mice (Schneider et al., 2014). Thus, in both 
short-term and long-term spatial memory tasks, the direction of the effect of treatment on memory 
performance reversed with age and improved in MWM in mice older than 5 months. Fear conditioning 
test, which refers to emotional memory tasks, provided further insight into short-term and long-term EFV 
effects on 5XFAD mice. Cue-dependent conditioning is based on associative learning among stimuli, 
which are mainly regulated by the amygdala-thalamo-cortical pathway; context-dependent conditioning is 
regulated by amygdalar–hippocampal communication (Orsini and Maren, 2012). Five- and nine-month 
old EFV-treated and untreated 5XFAD mice showed a similar freezing response to the US exposures 
during training (Fig. 4C). Nevertheless, the 5-month old EFV-treated mice had a greater percentage of 
freezing in the context-dependent fear test than the untreated mice of the same age, and the 9-month old 
EFV-treated mice displayed a similar level of freezing as untreated controls (Fig. 4D). In the cue-
dependent fear test, there was no difference between the treated and untreated groups at either 5- or 9-
months of age (4 and 8 months of EFF treatment, respectively, Fig. 4E). The results of the context-
dependent memory performance in 5-month old EFV-treated mice indicate an enhanced fear of context 
(inaccurate target) rather than cue (accurate target) after 4- but not 8-months of EFV treatment.  
 
3.5. EFV treatment reduces brain APP levels and gene expression in 5XFAD mice  
 
 An increase by genetic means of cerebral 24HC levels decreased the APP levels (Bryleva et al., 2010) 
and/or altered APP processing (Bryleva et al., 2010; Hudry et al., 2010) in mouse models of Alzheimer’s 
disease. Similarly, when treated with EFV, the APP levels were decreased in the 5XFAD model as well, 
by 40% (P = 0.03) and 30% (P = 0.15) at 5 and 9 months of age, respectively (Fig. 5A,D). Yet, the APP 
processing did not seem to be affected by EFV treatment as indicated by the quantifications of the APP 
cleavage fragments C99 and C83, produced as a result of amyloidogenic and non-amyloidogenic 
processing, respectively. C99 and C83, clearly visible in only 9-month old 5XFAD mice (Fig. 5E), 
showed a trend to a decrease upon EFV treatment when quantified individually (by 33% for C99, P = 
0.06, and by 35% for C83, P = 0.07), and a statistically significant decrease by 35% (P = 0.02), when 
quantified as the sum (Fig. 5F). The extent of these decreases (33-35%, Fig. 5F) was similar to that of 
APP (by 30%, Fig. 5D) suggesting that the C83 and C99 decreases is a consequence of the APP reduction 
and that neither amyloidogenic nor non-amyloidigenic APP processing was affected by EFV treatment, an 
interpretation also supported by the unchanged C83 to C99 ratio. 
 24HC is a potent activator of the transcription factors LXR receptors (Chen et al., 2007; Janowski et 
al., 1996), which control gene expression via activation, repression and transrepression (Saijo et al., 
2013). Hence, we assessed cerebral gene expression by whole transcriptome sequencing (RNA-Seq). 
About 22,560 genes were detected at 5 months in the 5XFAD brain, which represent ~90% of the mouse 
transcriptome (Fig. 5B). Of these genes, 13 had at least a 2.5-fold difference (an arbitrary cut off) in 
expression between EFV-treated and untreated 5XFAD mice and the positive false discovery rate q ≤ 
0.05. All 13 genes were downregulated (3.2-4.7-fold) in EFV-treated mice, and 9 of them were of 
relevance to Alzheimer’s disease: Alb (albumin) (Stanyon and Viles, 2012), Pomc (Pro-opiomelanocortin) 
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(Leone et al., 2013), Serpinas 3k and 1e (Serpin Peptidase Inhibitor 3 and 1, respectively) (Guan et al., 
2012; Maes et al., 2006), GC (Group-Specific Component or Vitamin D Binding Protein) (Moon et al., 
2013), Apoa1 and Apoa2 (Apolipoproteins A-I and A-II) (Lewis et al., 2010; Song et al., 2012), Apob 
(Apolipoprotein B) (Loffler et al., 2013; Namba and Ikeda, 1991), and Cyp2e1 (Cytochrome P450 2E1)  
(Van Ess et al., 2002). The 9 genes of relevance to Alzheimer’s disease were then assessed by qRT-PCR, 
which confirmed their decreased expression, from 5- to 15-fold in EFV-treated mice (Fig. 5C). Thus, 
EFV treatment affected gene expression, but none of the affected genes was the known target regulated 
by LXR activation; either these genes are indirect LXR targets or downregulated as a result of a reduced 
amyloid load due to EFV treatment. 
 
4. Discussion 
 
 The present study led to several major findings. First, cholesterol homeostasis is disturbed in the brain 
of 5XFAD mice, a widely used Alzheimer’s disease model. Second, a very low dose of the anti-HIV drug 
EFV stably activates CYP46A1 and promotes cholesterol turnover in the 5XFAD brain. Third, CYP46A1 
activation leads to a faster cholesterol homeostasis normalization in the 5XFAD brain. Finally, EFV 
treatment reduces amyloid-β burden as well as microglia activation in the brain of 5XFAD mice and 
ultimately improves mouse performance in MWM.  
 Previous work on a different mouse model of Alzheimer’s disease linked transgenic expression of 
mutant human APP and presenilin 1 and the alterations in brain cholesterol homeostasis (Vanmierlo et al., 
2010). Our sterol measurements (Fig. 1) are consistent with this link and suggest that several mechanisms 
can underlie dysregulation of cholesterol homeostasis in the 5XFAD brain. Prenatally, this is probably the 
APP overexpression, while postnatally, there is also a contribution of amyloid deposition. Indeed, 
cholesterol lowering in the 5XFAD brain (Fig. 1M) preceded the appearance of amyloid deposits at 
postnatal month 2 (Oakley et al., 2006), suggesting that it is likely the transgene expression that decreases 
initially cholesterol levels in the 5XFAD brain. This explanation is supported by studies in cultured 
neurons but not astrocytes showing that APP can interact with the transcription factor SREBP1 and 
prevent SREBP1 from maturation (Pierrot et al., 2013), thus decreasing cerebral cholesterol by decreasing 
cerebral cholesterol biosynthesis controlled by SREBPs. Also, in vitro, cholesterol was shown to bind to 
APP and affect its cleavage by the secretases (Barrett et al., 2012). Accordingly, cholesterol lowering in 
the 5XFAD brain can be due in part to cholesterol interaction with APP, the mechanism which will 
complement the APP-mediated reduction of the cholesterol biosynthesis rates. However, the APP 
lowering effect on cholesterol biosynthesis in the 5XFAD brain should be counteracted at some time 
point by another mechanism (likely SREBP maturation) to prevent cholesterol depletion. If operative in 
growing 5XFAD mice, this mechanism should lead to a slower decline in the cholesterol biosynthesis 
rates as compared to the B6SJL mice, exactly the effect that was observed in 2- and 3-month old animals 
(Fig. 1N). Prenatally, cholesterol input is not coupled to cholesterol elimination because CYP46A1 is 
barely detectable in the brain at postnatal week 1 and reaches its maximal expression only 2-3 weeks later 
(Lund et al., 1999). Accordingly, it is plausible that cholesterol homeostasis in the 5XFAD brain is 
dysregulated at birth because prenatal mechanisms controlling cholesterol biosynthesis rates are not well 
coordinated with and are not well compensated by cholesterol elimination.   
 Besides high levels of APP, the 5XFAD brain has a progressive amyloid deposition over the period of 
2 to 9 month of age (Oakley et al., 2006). In cell culture, amyloid-β1-40 peptide was found to inhibit 
cholesterol biosynthesis by inhibiting HMGCR, the rate-limiting enzyme in the production of cholesterol 
(Grimm et al., 2005). Also in cell culture, amyloid-β1-42 was demonstrated to reduce the levels of mature 
SREBP-2 and affect cholesterol biosynthesis (Mohamed et al., 2012). It is conceivable that these and 
probably other processes (Grosgen et al., 2010) can further disturb cholesterol maintenance in the 5XFAD 
brain, which is already compromised prenatally by the transgene expression.  As a result, cholesterol 
input and output in the adult 5XFAD brain are periodically uncoupled leading to the fluctuations of 
cerebral cholesterol (Fig. 1E). Only by 8 months of age, when amyloid deposition starts to level off, 
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cholesterol levels in the 5XFAD brain reach those in the B6SJL brain and the cholesterol-related 
processes seem to become coordinately regulated.  
 Despite aberrant cholesterol homeostasis, EFV dose ~100-times lower than that given to HIV patients 
(~0.1 mg/day/kg vs ~10 mg/day/kg) stably activated CYP46A1 in the 5XFAD brain (Fig. 1L,P). 
Importantly, this activation ultimately led to a compensatory increase in cerebral lathosterol but not 
desmosterol suggesting that it is cholesterol biosynthesis and turnover in neurons rather than astrocytes 
that mostly became enhanced. This result is consistent with normally neuron-specific CYP46A1 
expression in mice (Ramirez et al., 2008) and points to CYP46A1 as the primary EFV target. If so, 
cholesterol depletion from the brain of 2-4-month old EFV-treated mice was likely from neurons, thus 
providing an explanation for mixed results of behavioral tests on 5-month old 5XFAD mice after 4 
months of EFV treatment (Fig. 4). This treatment worsened mouse learning in Y-maze and MWM, 
improved mouse performance in the context-dependent fear test, and had no effect on the cue-dependent 
fear test. Conversely, no worsening in all three memory tests was detected in 9-month old 5XFAD mice 
after 8 months of EFV treatment, and the treatment significantly improved mouse learning in MWM. The 
eight-month treatment time even seemed to slow down behavioral deterioration related to age (Fig. 5B). 
EFV effects after 4 months of treatment may be confounded by the brain cholesterol depletion during the 
two months preceding behavioral evaluations (Fig. 1M). This depletion could be a result of the treatment 
starting when cholesterol pool in mouse brain was still expanding and cholesterol biosynthesis and 
metabolism were poorly coupled. In addition, there may be also the effect of the transgene expression. 
The former interpretation is supported by a lack of cholesterol depletion in the brain of normal C57BL/6J 
mice, whose treatment started at the age of 3 months, when cerebral cholesterol homeostasis was already 
stable (Mast et al., 2014). Yet, at 9 months of age, cerebral cholesterol was similar in EFV-treated and 
untreated 5XFAD mice for already 2 months prior to testing, and the confounding cholesterol reduction 
was absent. Alternatively, behavioral impairment could be a result of a neurotoxic effect of 24HC, whose 
small spike was observed in 5-month old 5XFAD mice after 4 months of EFV treatment (Fig. 1O). Some 
but not all studies in cell culture reported that 24HC may be cytotoxic (Kolsch et al., 1999) as well as 
potentiate the pro-apoptotic and pro-necrotic effects of amyloid-β1-42 peptide (Ferrera et al., 2008; Gamba 
et al., 2011). Regardless of the effect, enhanced cholesterol turnover in the brain with or without 
subsequent cholesterol depletion could be a tool to study and identify normal and pathological brain 
processes affected by cholesterol maintenance.  
 Three cerebral sterols (cholesterol, lathosterol, and 24HC) as well as cholesterol turnover were 
modulated in EFV-treated 5XFAD mice raising a question of how these sterols, each or collectively, 
contributed to the observed amelioration of amyloid pathology. Cerebral cholesterol was shown to 
regulate the production and amount of the amyloid-β peptides in vitro and cell cultures by modulating the 
activities of α- β-, and γ-secretases (Grosgen et al., 2010; Vance, 2012). Nevertheless, we do not believe 
that changes in cerebral cholesterol content were the underlying reason for a reduction in amyloid burden. 
First, the reductions of cellular/membrane cholesterol that modulated the secretase activities were massive 
(up to 70%) (Fassbender et al., 2001; Kojro et al., 2001; Simons et al., 1998; Wahrle et al., 2002). By 
contrast, in our 2-4 month old EFV-treated mice, the reductions of total cerebral cholesterol were much 
smaller, from 17% to maximum 37% (Fig. 1M). Second, the extent of the amyloid-β1-42 reduction was 
similar at 5 and 9 months age, despite at 5 months, cerebral cholesterol was much lower than at 9 months 
(Fig. 1M) as were the peptide accumulations (Fig. 4C,D).  
 Only 24HC and cholesterol turnover were increased to the same extent in 5- and 9-month old EFV-
treated 5XFAD mice (Fig. 1N,P) leading to a possible mechanistic model, which unifies EFV effects (Fig. 
6). In this model, EFV treatment activates CYP46A1 (Event 1) and increases the brain 24HC levels 
(Event 2) as well as the brain cholesterol turnover rate (Event 3). The latter increases cholesterol flux 
through the cellular membranes and inhibits APP processing (Event 4) via disruption of lipid rafts 
required for APP processing (Simons et al., 1998). Unprocessed APP is rapidly degraded (Chia and 
Gleeson, 2011), thus decreasing the APP levels (Fig. 5A,D). Increased 24HC content could also decrease 
the APP levels (Event 3') via inhibition of APP processing by non-membrane related mechanisms (Brown 
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et al., 2004). Increases in both 24HC and cholesterol turnover rate could have beneficial effects on mouse 
performance in MWM (Events 3" and 4') because of the suggested role of 24HC as a positive allosteric 
modulator of N-Methyl-D-Aspartate receptors (Paul et al., 2013; Sun et al., 2016a) and the role of the 
brain cholesterol turnover rate in the long term potentiation (Kotti et al., 2008; Kotti et al., 2006). Finally, 
24HC can bind to LXRs (Event 3''') (Chen et al., 2007; Janowski et al., 1996) and blunt the induction of 
pro-inflammatory genes in brain astrocytes, peripheral macrophages, and microglial cells (Joseph et al., 
2003; Kim et al., 2006; Lee et al., 2009; Zhang-Gandhi and Drew, 2007) via transrepression (Events 5, 5', 
and 5"). In astrocytes (Event 5), the downregulated genes include IL-1β (Zhang-Gandhi and Drew, 2007), 
which along with TNFα controls the expression of SERPINA3 (Das and Potter, 1995; Gitter et al., 2000; 
Machein et al., 1995; Morihara et al., 2005), human ortholog of Serpina3k (Heit et al., 2013) encoding α-
1-antichymotrypsin. Reduced expression of α-1-antichymotrypsin may reduce amyloid pathology (Events 
7 and 8) because α-1-antichymotrypsin was shown to directly bind to amyloid-β peptides and enhance 
their fibrillization and thereby plaque formation (Abraham and Potter, 1989; Eriksson et al., 1995; Ma et 
al., 1996; Ma et al., 1994). The LXR-mediated transrepression of inflammatory genes can also explain a 
decrease in microglia activation (Event 5") and downregulation of Serpina1e encoding α-1-antitrypsin 
(Event 5'). The expression of the target genes that are upregulated by LXRs, however, was not changed in 
mRNA-Seq (Fig. 5B), possibly due to a local, namely cell- and region-specific gene upregulation in 
astrocytes and microglia around amyloid plaques. Accordingly, these small changes in gene expression 
were not detected by RNA-Seq, which was conducted on whole brain homogenates. Alternatively, gene 
activation by LXRs was not operative upon EFV treatment, consistent with a lack of gene upregulation in 
CYP46A1 transgenic mice (Shafaati et al., 2011).  
 Several general similarities in the effects on the brain could be found between 5XFAD mice treated 
with EFV and animals with increased CYP46A1 expression due to: 1) genetic ablation of Acat1 in mice 
transgenic for mutant human APP, PS1, and MAPT (Bryleva et al., 2010); or 2) cerebral injections of the 
CYP46A1-containing adenovirus to APP23 mice (Hudry et al., 2010). In all three cases, the content of 
24HC in the whole brain or injected brain regions was increased, at least at the tested time points, whereas 
the amyloid-β1-42 levels were decreased, and cognitive deficits were ameliorated. Additional similarities 
include the APP reduction in EFV-treated 5XFAD mice and Acat1-/- triple transgenic mice, and the 
reduction in microglia activation in EFV-treated 5XFAD mice and CYP46A1-vector injected APP23 
mice. The differences also appear to exist but are difficult to directly compare due to different 
experimental set ups, evaluation times, and transgenic mouse modes used. 
 In summary, oral administration of a small dose of the anti-HIV drug EFV to a mouse model of 
Alzheimer’s disease ameliorated amyloid pathology in the brain and led to changes supporting therapeutic 
potential of cholesterol-metabolizing enzyme CYP46A1, its metabolite 24HC and 24HC-mediated LXR 
transrepression of some of the inflammatory genes in astrocytes and microglia surrounding amyloid 
plaques.  
 
5. Conclusions 
 
 Collectively, our findings support the potential of CYP46A1 as a pharmacologic target for 
Alzheimer’s disease and that EFV should be tested for CYP46A1 activation in a clinical trial.  
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FIGURE LEGENDS 
 
Fig. 1. Sterol profiles in the brain of B6SJL and 5XFAD mice, EFV untreated (Utx) or treated (Tx). 
Age-dependent changes were monitored in 1- to 9-month old animals. Gray asterisks are significant 
changes in Utx 5XFAD mice vs the background B6SJL strain; black asterisks are significant changes in 
Tx 5XFAD mice vs Utx 5XFAD mice. The results are mean ± SD of the measurements in individual 
animals (n=3-7 male mice per group and time point). *, P ≤ 0.05; **, P ≤ 0.01; and ***, P ≤ 0.001 by 
repeated measures two-way ANOVA followed by a post hoc Bonferroni multiple comparison test. (M-P) 
To clearly see the overlaid sterol profiles, the statistical significance data (asterisks) are not indicated in 
these panels. 
 
Fig. 2. CYP46A1 activation reduces dense-core amyloid plaques in 5-month old EFV-treated mice. 
A) Representative images of the brain sections (7-10 male mice per group) stained with ThioS (green). 
Nuclei were detected by propidium iodide and false colored in blue. B6SJL mice served as a negative 
control. Scale bars are 1 mm. B) Quantification of the Thioflavin S-positive plaques. Error bars indicate 
SD. *P ≤ 0.05 by a two-tailed, unpaired Student’s t-test. 
 
Fig. 3. CYP46A1 activation reduces diffuse-core amyloid plaques and microglia activation in 5- and 
9-month old EFV treated mice. A) Representative images of the brain sections (3-4 male mice per 
group) showing the anti-6E10 immunoreactivity (red) for diffuse-core amyloid plaques and anti-Iba1 
immunoreactivity (green) for activated microglia. Nuclei were stained with DAPI. B6SJL mice served as 
a negative control. Scale bars are 1 mm. B) Quantification of the 6E10-positive amyloid plaques and 
Iba1-positive cells. Error bars indicate SD. C and D) Quantification of soluble and insoluble amyloid-β 
peptides by ELISA. Error bars indicate SD. Only males (n=12-13, colored in blue) were used for the 
measurements in 5 month-old animals; both males (n=4-5) and females (n=4, colored in pink) were used 
for the measurements in 9 month-old animals. Rectangles and spheres denote amyloid-β1-42 and amyloid-
β1-40 peptides, respectively. Black asterisks are significant changes between the groups comprised of both 
males and females; blue asterisks are significant changes between the groups comprised of males only; 
pink asterisks are significant changes between the groups comprised of females only. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, **** P ≤  0.0001  by a two-tailed, unpaired Student’s t-test.  
 
Fig. 4. EFV effects on behavior in 5- and 9-month old 5XFAD mice. Utx, untreated animals; Tx, 
treated animals; US, unconditioned stimulus; and CS, conditioned stimulus. Bars represent mean ± SEM. 
A and D) *, P ≤ 0.05 by a two-tailed, unpaired Student’s t-test. B and C) *, P ≤ 0.05; and ***, P ≤ 0.001 
by a two-way ANOVA with treatment group and trial factors, followed by a Bonferroni corrections as a 
post hoc comparison if needed.  
 
Fig. 5. Effects of CYP46A1 activation on APP and gene expression. A and D) Representative Western 
blots (n=6-8 mice per group of 5- and 9-month old males) showing the reduction in the brain levels of 
APP. The relative APP expression is presented below the Western blot and is normalized per β-actin. At 5 
months of age, the APP reduction was statistically significant, P = 0.03 by a two-tailed, unpaired 
Student’s t-test. At 9 months of age, the reduction was not significant, P = 0.15, and only represents a 
trend.  B) The Volcano plot showing the reductions in the gene expression of EFV-treated vs untreated 
mice as indicated by mRNA sequencing of the whole brain transcriptome. The vertical dashed lines are 
the boundaries of a 2.5-fold change in gene expression (an arbitrary cut off); the horizontal dashed line is 
the boundary of the P value of 0.05. Genes with ≥ 2.5-fold change and q ≤ 0.05 are indicated, and those of 
pertinence to AD are also colored in orange. Three mice per group were used as biological replicates; all 
6 were littermates. C) Quantifications by qPCR confirming a reduction in gene expression in EFV-treated 
vs untreated 5XFAD mice indicated by the transcriptome sequencing. The results are mean ± SD of the 
measurements in individual mice. E) Representative Western blot (n=7 mice per group) showing the 
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expression of the APP cleavage fragments C99 and C83. The relative fragment expression is normalized 
per GAPDH. (F) Quantifications of the C99 and C83 fragments: individual, as a sum (C83 + C99), and as 
the ratio (C83/C99). Error bars indicate SD. *, P ≤ 0.05 by a two-tailed, unpaired Student’s t-test. 
 
Fig. 6. Proposed model unifying EFV effects. The sequence of events is numbered chronologically with 
primes (','',''') indicating events that may occur simultaneously. Events in black above black arrows are 
those supported experimentally by the present work; events in gray above gray arrows are putative and 
suggested, in most cases, on the basis of literature data. Thin and thick black lines underline events after 
4- and 8-months of EFV treatment, respectively. Events 1 and 2: CYP46A1 is the only enzyme in mice 
that can produce 24HC in the brain (Lund et al., 1999), hence an increase in the brain 24HC levels 
measured in Fig. 1D-P provides evidence for enzyme activation by EFV. Event 3 is supported by an 
increase in the brain lathosterol levels triggered by an increase in the 24HC levels (Fig. 1B-N). Events 3' 
and 4 are supported by a decrease in the APP levels in EFV-treated mice (Fig. 5A,B) as well as the 
literature data summarized in Discussion ((Brown et al., 2004; Chia and Gleeson, 2011; Simons et al., 
1998). Events 3" and 4' are supported by improved performance of EFV-treated mice after 8 months of 
drug treatment in Morris water maze tasks (Fig. 4B) and also literature data presented in Discussion 
(Kotti et al., 2008; Kotti et al., 2006; Paul et al., 2013; Sun et al., 2016a). Event 3''' cannot be measured in 
vivo directly, only indirectly by measuring the expression of the target genes in cells of interest. Events 5, 
5', and 5": neuroinflammation, a hallmark of Alzheimer’s disease brain, is characterized by the presence 
of activated astrocytes and microglia around amyloid plaques (Akiyama et al., 2000; Cameron and 
Landreth, 2010; Schwab and McGeer, 2008). LXRs are suggested to exert anti-inflammatory effects in 
multiple cell type and contexts by inhibiting the transcription of the NF-κB-regulated proinflammatory 
genes such as IL-1β and TNFα (Ghisletti et al., 2007). Event 5" is supported by a reduction in brain 
microglia activation as a result of EFV treatment (Fig. 3A). Event 5 is supported by a lowered Serpina3k 
expression in the whole brain transcriptome of EFV-treated mice (Fig. 5B) and data that in Alzheimer’s 
disease brain and mouse models of this disease, plaque-surrounding activated astrocytes have elevated 
levels of α-1-antichymotrypsin encoded by SERPINA3 (Abraham et al., 1988; Licastro et al., 1998; 
Nilsson et al., 2001), a human ortholog of Serpina3k. Events 5' and 6: Serpina1e and Serpina3k, the two 
acute phase genes, are downregulated in EFV-treated mice (Fig. 5B,C) indicating a decrease in 
inflammatory response in infiltrating brain macrophages and brain astrocytes, respectively (Schmechel 
and Edwards, 2012; Styren et al., 1998). This downregulation is also consistent with a reduction in brain 
microglia activation as a result of EFV treatment (Fig. 3A). Furthermore, Events 5' and 6 are supported by 
a lowered Serpina3n expression in APP transgenic mice treated with the synthetic LXR agonist 
T0901317; these mice have a decrease in insoluble amyloid-β peptide along with a suppression of 
inflammatory response (Lefterov et al., 2007). The beneficial role of activated LXRs in amyloid 
pathology is also supported by an increase in amyloid plaque load in APP/presenillin transgenic mice 
lacking LXRs and showing no inhibition of the inflammatory response of glial cells to amyloid-β fibrils 
(Zelcer et al., 2007). Finally, Event 7 is supported by the literature data  (Abraham and Potter, 1989; 
Eriksson et al., 1995; Ma et al., 1996; Ma et al., 1994), and Event 8 by amyloid burden reduction in EFV-
treated mice (Figs. 3C,D).  
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